Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15107521 | 1.00 | GLP1R (0.48) | GLP1REPHX2ADRA1AKDM4ECES2 | |
| SCHEMBL12673887 | 1.00 | GLP1R (0.48) | GLP1REPHX2ADRA1AKDM4ECES2 | |
| SCHEMBL21242757 | 0.97 | GLP1R (0.49) | GLP1REPHX2ADRA1AKDM4ETSHR | |
| SCHEMBL8234605 | 0.97 | GLP1R (0.49) | GLP1REPHX2ADRA1AKDM4ETSHR | |
| SCHEMBL14240910 | 0.97 | GLP1R (0.47) | GLP1REPHX2ADRA1AKDM4ECES2 | |
| SCHEMBL12666197 | 0.97 | GLP1R (0.47) | GLP1REPHX2ADRA1AKDM4ECES2 | |
| SCHEMBL12666120 | 0.97 | GLP1R (0.47) | GLP1REPHX2ADRA1AKDM4ECES2 | |
| SCHEMBL15259303 | 0.96 | GLP1R (0.48) | GLP1REPHX2ADRA1AKDM4ECES2 | |
| SCHEMBL19369668 | 0.96 | GLP1R (0.44) | GLP1REPHX2ADRA1ACES2TSHR | |
| SCHEMBL16478824 | 0.93 | TSHR (0.45) | GLP1REPHX2ADRA1ACES2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3065767-B1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA AS (DK) | 2020-12-30 | — | — | EP | disclosed |
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2019-04-18 | — | — | US | disclosed |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2019-04-16 | — | — | US | disclosed |
| US-9688737-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2017-06-27 | — | — | US | disclosed |
| EP-2910570-B1 | Protease stabilized, acylated insulin analogues | NOVO NORDISK AS (DK) | 2016-10-12 | — | — | EP | disclosed |
| EP-2254906-B1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| EP-2910571-B1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| EP-2910569-B1 | Protease stabilized, acylated insulin analogues | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| WO-2016119854-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL INSULIN ADMINISTRATION COMPRISING A TABLET CORE AND A POLYVINYL ALCOHOL COATING | NOVO NORDISK A/S (DK) | 2016-08-04 | — | — | WO | disclosed |
| US-20160193154-A1 | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating | NOVO NORDISK A/S (DK) | 2016-07-07 | — | — | US | disclosed |
| US-20140357838-A1 | N-Terminally Modified Insulin Derivatives | NOVO NORDISK A/S (DK) | 2014-12-04 | — | — | US | disclosed |
| US-20140315797-A1 | Novel N-Terminally Modified Insulin Derivatives | NOVO NORDISK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2014-03-13 | — | — | US | disclosed |
| US-20130244931-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2013-09-19 | — | — | US | disclosed |
| US-8486890-B2 | Amylin derivatives | NOVO NORDISK A/S (DK) | 2013-07-16 | — | — | US | disclosed |
| WO-2013093009-A1 | N -TERMINALLY MODIFIED INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-06-27 | — | — | WO | disclosed |
| WO-2012049307-A2 | NOVEL N-TERMINALLY MODIFIED INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-04-19 | — | — | WO | disclosed |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| WO-2009115469-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | WO | disclosed |
| WO-2007104789-A2 | AMYLIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357838-A1 | N-Terminally Modified Insulin Derivatives | IAPP, INSR, PTMS | GLP1R 12/4885EPHX2 4067/4885ADRA1A 4293/4885 |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885EPHX2 4491/4885ADRA1A 2463/4885 |
| US-20140315797-A1 | Novel N-Terminally Modified Insulin Derivatives | IAPP, INSR, IRS1 | GLP1R 12/4885EPHX2 4739/4885ADRA1A 3071/4885 |
| US-20160193154-A1 | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating | IAPP, INSR, GPR119 | GLP1R 26/4885EPHX2 3632/4885ADRA1A 3243/4885 |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885EPHX2 4491/4885ADRA1A 2463/4885 |
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885EPHX2 4491/4885ADRA1A 2463/4885 |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | IAPP, IDE, LIPE | GLP1R 54/4885EPHX2 4657/4885ADRA1A 2754/4885 |
| US-20130244931-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | GLP1R 1/4885EPHX2 4797/4885ADRA1A 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.